Anabolic steroid-induced hypogonadism: diagnosis and treatment.

Dean Destructo

New member
Fertil Steril. 2014 May;101(5):1271-9. doi: 10.1016/j.fertnstert.2014.02.002. Epub 2014 Mar 14.
[h=1]Anabolic steroid-induced hypogonadism: diagnosis and treatment.[/h]Rahnema CD1, Lipshultz LI2, Crosnoe LE1, Kovac JR2, Kim ED3.
[h=3]Author information[/h]

[h=3]Abstract[/h][h=4]OBJECTIVE:[/h]<abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">To develop an understanding of hypogonadal men with a history of anabolic-androgenic steroid (AAS) use and to outline recommendations for management.</abstracttext>
[h=4]DESIGN:[/h]<abstracttext label="DESIGN" nlmcategory="METHODS">Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria.</abstracttext>
[h=4]SETTING:[/h]<abstracttext label="SETTING" nlmcategory="METHODS">Not applicable.</abstracttext>
[h=4]PATIENT(S):[/h]<abstracttext label="PATIENT(S)" nlmcategory="METHODS">Men seeking treatment for symptomatic hypogonadism who have used nonprescribed AAS.</abstracttext>
[h=4]INTERVENTION(S):[/h]<abstracttext label="INTERVENTION(S)" nlmcategory="METHODS">History and physical examination followed by medical intervention if necessary.</abstracttext>
[h=4]MAIN OUTCOME MEASURES(S):[/h]<abstracttext label="MAIN OUTCOME MEASURES(S)" nlmcategory="METHODS">Serum testosterone and gonadotropin levels, symptoms, and fertility restoration.</abstracttext>
[h=4]RESULT(S):[/h]<abstracttext label="RESULT(S)" nlmcategory="RESULTS">Symptomatic hypogonadism is a potential consequence of AAS use and may depend on dose, duration, and type of AAS used. Complete endocrine and metabolic assessment should be conducted. Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators.</abstracttext>
[h=4]CONCLUSION(S):[/h]<abstracttext label="CONCLUSION(S)" nlmcategory="CONCLUSIONS">Although complications of AAS use are variable and patient specific, they can be successfully managed. Treatment of ASIH depends on the type and duration of AAS use. Specific details regarding a patient's AAS cycle are important in medical management.</abstracttext>
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.


[h=4]KEYWORDS:[/h]Anabolic-androgenic steroids; androgens; clomiphene citrate; erectile dysfunction; gynecomastia; human chorionic gonadotropin; hypogonadotropic hypogonadism; tamoxifen; testicular atrophy

[h=3]Comment in[/h]

<dl class="rprtid" style="margin-right: 15px; margin-left: 0px; font-size: 0.8465em; line-height: 1.4em; display: inline;"><dt style="display: inline; padding: 0px; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px !important; white-space: nowrap;">PMID:</dt> <dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap;">24636400</dd> <dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap;">[PubMed - indexed for MEDLINE]</dd></dl>
 
Back
Top